ORX

Orexo

Research update

Print

Orexo: Zubsolv Rx data - September

The market share (rolling 4 weeks average) for Zubsolv declined slightly in September to 5.26% (5.32), and TRx reached a market share of 5.11% (5.19%). The overall market for buprenorphine/naloxone based opioid addiction treatments continues to show a healthy growth rate. In September (rolling 4 weeks average) the y/y TRx growth rate was 9.6% (10.6%) and 10.1% (10.5%) in volume.

Continue reading (pdf) icon-download